The spread of drug-resistant malaria parasites urges the search for new antimalarial drugs. Malarial aspartic proteases – plasmepsins (Plms) – are attractive drug targets. In collaboration with the group of Prof. A. Jirgensons (Institute of Organic Synthesis), we are involved in the development of Plm inhibitors as antimalarial drugs.
46. Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity